Paper Details

  1. Home
  2. Paper Details

Edaravone for acute ischemic stroke - Systematic review with meta-analysis.

Author: AfreixoVera, FidalgoMariana, GregórioHugo, GregórioTiago, MagalhãesPedro, Ricardo PiresJoana, ViseuInês

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Stroke is a major cause of death and disability. While treatments exist to restore blood flow to the brain, they only work within a limited time frame, and most people aren't eligible. A medication called edaravone has been shown to help reduce brain damage in some stroke patients.
Paper Details　
Original Abstract of the Article :
Ischemic stroke is a major cause of death and disability. Despite major advances in reperfusion therapies, most patients don´t benefit from these treatments as the time window for such interventions is limited. Therefore, other treatment options are desirable. Edaravone has been demonstrated in prev...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clineuro.2022.107299

データ提供：米国国立医学図書館（NLM）

Edaravone: A Potential New Weapon in the Fight Against Ischemic Stroke

Ischemic stroke, a major cause of death and disability, remains a significant public health concern. While reperfusion therapies have improved outcomes for some patients, their effectiveness is limited by a narrow time window for intervention. This research explores the potential of edaravone, a neuroprotective agent, as an alternative treatment option for acute ischemic stroke. The researchers conducted a systematic review and meta-analysis of existing studies to assess edaravone's efficacy in reducing neurological deficits in stroke patients.

Edaravone Shows Promise in Stroke Recovery

The meta-analysis revealed that edaravone significantly reduced neurological deficits in stroke patients compared to placebo. This suggests that edaravone may offer a promising therapeutic approach for improving outcomes in ischemic stroke patients, particularly those who are not eligible for reperfusion therapies.

A New Hope for Stroke Patients

The research findings highlight the potential of edaravone as a valuable addition to the treatment arsenal for acute ischemic stroke. Further research is needed to optimize edaravone's administration and identify the most suitable patient populations for its use. These findings offer new hope for stroke patients, potentially expanding treatment options and improving recovery outcomes.

Dr.Camel's Conclusion

The desert of stroke recovery can be a challenging journey, but edaravone may offer a new oasis of hope for patients. This research suggests that edaravone holds promise as a neuroprotective agent, potentially improving outcomes for stroke patients who are not eligible for traditional therapies. As we delve deeper into the potential of edaravone, we may discover new ways to navigate the path to stroke recovery.

Date :
  1. Date Completed 2022-08-09
  2. Date Revised 2022-08-16
Further Info :

Pubmed ID

35753163

DOI: Digital Object Identifier

10.1016/j.clineuro.2022.107299

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.